Simplex Trading Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Simplex Trading reduced its stake in Amgen by 19.33% during the most recent quarter end. The investment management company now holds a total of 27,673 shares of Amgen which is valued at $4,517,617 after selling 6,632 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 18, 2016.Amgen makes up approximately 0.57% of Simplex Trading’s portfolio.

Other Hedge Funds, Including , Fox Run Management L.l.c. added AMGN to its portfolio by purchasing 5,800 company shares during the most recent quarter which is valued at $946,850. Amgen makes up approx 0.44% of Fox Run Management L.l.c.’s portfolio.Capital Advantage boosted its stake in AMGN in the latest quarter, The investment management firm added 36 additional shares and now holds a total of 2,259 shares of Amgen which is valued at $368,059. Amgen makes up approx 0.13% of Capital Advantage’s portfolio.Handelsbanken Fonder Ab reduced its stake in AMGN by selling 12,000 shares or 9.47% in the most recent quarter. The Hedge Fund company now holds 114,673 shares of AMGN which is valued at $18,683,672. Amgen makes up approx 0.74% of Handelsbanken Fonder Ab’s portfolio.Capital Asset Advisory Services boosted its stake in AMGN in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 2,494 shares of Amgen which is valued at $400,337. Amgen makes up approx 0.52% of Capital Asset Advisory Services’s portfolio.

Amgen opened for trading at $162.45 and hit $163.65 on the upside on Wednesday, eventually ending the session at $163.25, with a gain of 0.47% or 0.76 points. The heightened volatility saw the trading volume jump to 21,61,425 shares. Company has a market cap of $122,636 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *